People diagnosed with type 2 diabetes might benefit soon from Eli Lilly's new orforglipron weight loss drug following its ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of ...

An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB) ...

Savvy pharma-stock investors know that an oral GLP-1 drug from Novo Nordisk called Rybelsus has been on the market as a ...

One of those is Boston-based Syntis Bio, which is working on a daily pill that mimics the effects of gastric bypass—no actual ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

NU-9 targets a shared underlying mechanism found in various neurodegenerative diseases. A new study from Northwestern ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

WEDNESDAY, April 9, 2025 (HealthDay News) -- An experimental drug can help patients with advanced multiple sclerosis (MS) delay the progressive disability that comes with their disorder ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

In a Johns Hopkins Children’s Center study, the addition of navitoclax to the standard TB treatment significantly increased ...